Back to Archived Journals » Patient Intelligence » Volume 2 » Default

Application of PIP data in health economic models for market access

Authors van Dongen N, Nuijten MJ

Published 24 November 2010 Volume 2010:2 Pages 53—58


Review by Single-blind

Peer reviewer comments 2

Nadine van Dongen1, Mark JC Nuijten2
1Van Dongen Research Ltd, London, UK; 2Ars Accessus Medica, Amsterdam, The Netherlands

Abstract: Cost-effectiveness data from a state of the art health economic analysis should permit reliable, reproducible, and verifiable insights into the effectiveness of a drug and the possible savings that might be achieved relative to other drugs and/or treatments. The data for a model may come from a variety of sources and are subject to varying degrees of uncertainty. The reliability of the estimates depends on the choice of the data sources. Data sources for the variables being used in a model may be clinical trials, databases, medical records, and Delphi panels. A limitation of these data sources is that they often lack the input from the patient’s perspective. Patient Intelligence applications can provide data to be used in health economic models for any given situation regarding treatment of persons suffering from a disorder, disease, or complaint. The objective of this paper to explore the opportunity of integrating patient data generated by Patient Intelligence applications as an alternative data source for a Delphi panel and databases in health economic models.

Keywords: effectiveness, Patient Intelligence, data source, Delphi panel

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]